Trials and therapies in secondary progressive MS, simplified

Navid Manouchehri, Olaf Stüve

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

The FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.

Original languageEnglish (US)
Pages (from-to)431-432
Number of pages2
JournalNature Reviews Neurology
Volume15
Issue number8
DOIs
StatePublished - Aug 1 2019

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Trials and therapies in secondary progressive MS, simplified'. Together they form a unique fingerprint.

  • Cite this